This invention relates to immunoturbidimetric and spectrophotometric analysis of plasma for proteins.
Clinical laboratory tests are routinely performed on serum or plasma of whole blood. In a routine assay, red blood cells are separated from plasma by centrifugation, or red blood cells and various plasma proteins are separated from serum by clotting prior to centrifugation.
Haemoglobin (Hb), bilirubin (BR), biliverdin (BV), and light-scattering substances like lipid particles are typical substances which will interfere with and affect spectrophotometric and other blood analytical measurements. Such substances are referred to generally, and in this specification as interferents. Elevated BR and BV referred to as bilirubinemia and biliverdinemia respectively can be due to disease states, increased lipid particles in the blood also known as lipemia, can be due to disease states and dietary conditions; elevated Hb in the blood known as haemoglobinemia can be due to disease states and as a result of sample handling.
Many tests conducted on plasma or serum samples employ a series of reactions which terminate after the generation of chromophores which facilitate detection by spectrophotometric measurements at one or two wavelengths. Measurement of the quantity of interferents in a sample prior to conducting such tests is important in providing meaningful and accurate test results. In fact if a sample is sufficiently contaminated with interferents, tests are normally not conducted as the results will not be reliable.
Current methods used for detecting haemoglobinemia, bilirubinemia and lipemia or turbidity utilize visual inspection of the sample with or without comparison to a color chart. Visual inspection is sometimes employed on a retrospective basis where there is a disagreement between test results and clinical status of the patient in order to help explain such discrepancies.
Pre-test screening of samples by visual inspection is semi-quantitative at best, and highly subjective and may not provide sufficient quality assurance as required for some tests. Furthermore, visual inspection of samples is a time consuming, rate limiting process. Consequently, state-of-the-art blood analyzers in fully and semi automated laboratories do not employ visual inspection of samples.
Other methods used to assess the amount of contamination of a sample, i.e., sample integrity, employ direct spectrophotometric measurement of a diluted sample in a special cuvette. In order to obtain a measurement of the sample of the plasma or serum, sample tubes must be uncapped, a portion of the sample taken and diluted prior to measurement. Both of these steps are time consuming and require disposable cuvettes.
An apparatus used for measuring sample integrity can also be used to measure plasma proteins, e.g., Immunoglobulin A (IgA), β2-microglobulin and C-reactive protein (CRP). To do so, an antibody reagent is required for each protein, and a 37° C. incubation chamber. This method of analysis is called immunoturbidimetry because the specific antibody reagent forms immunocomplexes with the corresponding protein, when present in the sample. The immunocomplexes scatter light in various directions depending on the size distribution of the immunocomplexes or particles; turbidity in a sample is a result of scattered light and the absorbance increase is inversely proportional to wavelength. It must be understood that the use of the term absorbance includes “true absorbance” and the effect of light loss by any other means; the detector in the spectrometer measures the light transmitted through the sample, and absorbance is calculated as the negative log of transmittance. Therefore, any light which does not reach the detector, e.g., due to scattering caused by turbidity, will be interpreted as absorbed light.
For proteins in low concentrations, e.g., in the order of mg/L, the turbidity created by immunocomplexes is very small and are usually measured in one of two ways: 1) Measurement of light scattered in the forward direction on an instrument called a nephelometer, which is like a spectrophotometer that measures light propagated at an acute angle to the incident light. Such a method would require a separate instrument which would increase the cost per test; 2) Measurement of “absorbance” at 340 nm by a spectrophotometer. In the prior art which uses absorbance measurements, the absorbance at 340 nm at zero time is subtracted from the absorbance at 340 nm after incubation at approximately 37° C. for approximately five minutes, in order to remove the effect of sample interferents. This approach cannot be used for the near infrared (NIR) and adjacent visible wavelengths where the light-scattering caused by the immunocomplexes is very small.
It is desirable to use an apparatus designed for measuring plasma and serum interferents to perform immunoturbidimetric measurements. This feature allows tests which are not available on general chemistry analyzers, to become available, and at the same time the apparatus can provide a screening system for serum and plasma interferents.
The present invention uses a novel wavelength range and method to subtract endogenous sample turbidity and the effect of other interferents. The present invention uses a disposable dispensing tip in a novel way both as a reaction and incubation chamber, as well as a cuvette. The use of a disposable dispensing tip as a reaction chamber and cuvette allows this invention to be integrated into a chemistry analyzer, or built as a stand-alone instrument for measuring serum and plasma interferents as well as plasma proteins. This invention is particularly relevant to chemistry analyzers which do not already possess similar optical hardware as described for this invention, which could facilitate the measurement of serum and plasma interferents, and plasma proteins. By integrating such optical capabilities in the chemistry analyzer, the current test menu can be expanded by offering immunoturbidimetric measurements.
Accordingly, the present invention provides an apparatus for determining the concentration of one or more plasma proteins in a sample by immunoturbidimetry, said apparatus comprising:
a blood analyzer;
a disposable dispensing tip;
means for sealing a first end of the disposable dispensing tip;
a second tip capable of being inserted into an open second end of the disposable dispensing tip for adding one or more reagents to the disposable dispensing tip; a heated cavity for receiving the sample in the disposable dispensing tip of the analyzer;
means for transferring the disposable dispensing tip into and out of the heated cavity;
a radiation source for emitting a beam of radiation;
means for directing the radiation onto the sample in the disposable dispensing tip;
a sensor responsive to receipt of the radiation; and
means for correlating said concentration of the one or more proteins in the sample to a sensor response from the sample. Preferably the means for sealing is a vice and the radiation source means, means for directing said radiation onto said sample, and sensor are contained in a spectrophotometer. More preferably the beam of radiation is near infrared and adjacent visible region light and has wavelengths from about 475 nm to about 910 nm.
An apparatus of the invention for the correlation referred to above incorporates calibration algorithms in respect of IgA, β2-microglobulin and C-reactive protein (CRP) respectively which are:
mg/L IgA=−a(X nm)+b(Y nm)−c a.
where a, b and c are coefficients of the first derivative of absorbances at the wavelengths X and Y; (X nm) is the first derivative of the absorbance at wavelength X; (Y nm) is the first derivative of the absorbance at wavelength Y; preferably a=3327100-3327120, b=484250-484290 and c=70-85, more preferably a=3327114.33, b=484270.80 and c=77.3; where X is about 780-800 nm, and Y is about 820-830 nm, preferably X is about 789 nm and Y is about 825 nm.
mg/L β2-microglobulin=a(X nm)+b(Y nm)+c b.
where a, b and c are coefficients of the first derivative of absorbances at wavelengths X and Y; (X nm) is the first derivative of the absorbance at wavelength X; (Y nm) is the first derivative of the absorbance at wavelength Y; preferably a=−33640-33660, b=36550-36560 and c=2-3, more preferably a=−33648.79, b=36556.81 and c=2.3; where X is about 545-550 nm and Y is about 825-835 nm, preferably X is about 548 nm and Y is about 829 nm;
mg/L CRP=a(X nm)+b(Y nm)+c c.
where a, b and c are coefficients of the first derivative of absorbances at wavelengths X and Y; (X nm) is the first derivative of the absorbance at wavelength X; (Y nm) is the first derivative of the absorbance at wavelength Y; preferably a=(−1813675)-(−1813685), b=1808670-1808680 and c=9.5-10, more preferably a=−1813682.71, b=1808677.58 and c=9.8; where X is about 655-665 nm and Y is about 675-685 nm, preferably X is about 661 nm and Y is about 679 nm.
In another aspect the invention, there is provided a method for determining the concentration of one or more plasma proteins in a sample by immunoturbidimetry in a blood analyzer, the method comprising:
filling a disposable dispensing tip with the sample;
sealing a first end of the tip with means for sealing;
adding a reagent to an open second end of the disposable dispensing tip with a second tip capable of being inserted into the open end;
placing the disposable dispensing tip into a heated cavity;
radiating the sample in the disposable dispensing tip with a source which emits a beam of radiation;
sensing the radiation having passed through the sample;
correlating the concentration of said one or more proteins in said sample to the sensor response from the sample. The disposable dispensing tip which contains the reagent or reagents and sample may be removed from the heated cavity prior to being subjected to radiation, The preferred means for sealing is a vice. The method also contemplates that the beam of radiation is near infrared and adjacent visible region light, preferably the near infrared and adjacent visible region light has wavelengths from about 475 nm to about 910 nm.
Concerning this method the correlation referred to above incorporates calibration algorithms in respect of IgA, β2-microglobulin and C-reactive protein (CRP) respectively which are:
mg/L IgA=−a(X nm)+b(Y nm)−c a.
where a, b and c are coefficients of the first derivative of absorbances at the wavelengths X and Y; (X nm) is the first derivative of the absorbance at wavelength X; (Y nm) is the first derivative of the absorbance at wavelength Y; preferably a=3327100-3327120, b=484250-484290 and c=70-85, more preferably a=3327114.33, b=484270.80 and c=77.3; where X is about 780-800 nm, and Y is about 820-830 nm, preferably X is about 789 nm and Y is about 825 nm
mg/L β2-microglobulin=a(X nm)+b(Y nm)+c b.
where a, b and c are coefficients of the first derivative of absorbances at wavelengths X and Y; (X nm) is the first derivative of the absorbance at wavelength X; (Y nm) is the first derivative of the absorbance at wavelength Y; preferably a=−33640-33660, b=36550-36560 and c=2-3, more preferably a=−33648.79, b=36556.81 and c=2.3; where X is about 545-550 nm and Y is about 825-835 nm, preferably X is about 548 nm and Y is about 829 nm;
mg/L CRP=a(X nm)+b(Y nm)+c c.
where a, b and c are coefficients of the first derivative of absorbances at wavelengths X and Y; (X nm) is the first derivative of the absorbance at wavelength X; (Y nm) is the first derivative of the absorbance at wavelength Y; preferably a=(−1813675)-(−1813685), b=1808670-1808680 and c=9.5-10, more preferably a=−1813682.71, b=1808677.58 and c=9.8; where X is about 655-665 nm and Y is about 675-685 nm, preferably X is about 661 nm and Y is about 679 nm.
The present invention also provides a method for determining the concentration of plasma protein IgA, β2-microglobulin or C-reactive protein in a plasma sample by immunoturbidimetry in a blood analyzer, said method comprising:
As discussed above, the present invention provides apparatus and a method for performing immunoturbidimetric measurements on an apparatus used for measuring plasma and serum interferents. This feature allows tests which are not available on general chemistry analyzers, to become available, and at the same time the apparatus can provide a screening system for serum and plasma interferents. The apparatus for measuring serum and plasma interferents comprises a housing for receiving a sample; a radiation source; a sensor; a means for optically connecting the radiation source with the sensor along a sample path through the housing and along a reference path which bypasses the sample; a means for selectively passing a beam from the sample path and from the reference path to the sensor; and a means for correlating a sensor response, from the sample path relative to a sensor response from the reference path, to a quantity of a known substance in said sample. The sample housing can be an integral part of the conveyor system as shown in
The apparatus further comprises a quartz-tungsten-halogen lamp capable of emitting a near infrared, and adjacent visible region light beam having wavelengths from 475 nm to 910 nm and a bifurcated fibre-optic cable for splitting the light beam from the quartz-tungsten-halogen lamp into a sample path beam for travel along a sample path and a reference path beam for travel along a reference path. This apparatus further comprises a shutter for selectively blocking the sample path light beam which travels along the sample path and the reference path light beam which travels along the reference path, as well as optical fibre bundles for transmitting the sample path light beam through a sample enclosed in the housing, and optical fibre bundles for transmitting the sample path light beam from the sample to a second bifurcated fibre-optic cable, where the beam from the sample path and the beam from the reference path converge into a single fibre-optic cable. It is understood that any means for excluding from the sample, light other than that from the radiation source of the apparatus, is within the scope of this invention. Also, if dark current, i.e., sensor response when sensor is not exposed to the instrument light, is subtracted from both the reference and sample measurements, the room light impinging on the detector can be effectively subtracted without affecting the instrument performance significantly.
Preferably, the bottom end of the dispensing tip is sealed by flattening between the jaws of a small vice, after a sample is aspirated into said tip. Preferably the dispensing tip is disposable and more preferably the tip of an analyzer is used as a reaction and incubation chamber after the tip is sealed with the sample inside, and the same sealed dispensing tip is used as a cuvette.
Analytes, such as proteins, preferably Immunoglobulin A (IgA), β2-microglobulin and C-reactive protein (CRP), can be measured on the apparatus through the use of reagents, eg. antibodies, by the process of immunoturbidimetry. Each plasma protein requires a specific antibody, and the specificity of each test can be increased by subtracting the first derivative of the absorbance at zero time from the first derivative of absorbance after approximately 2 minutes at 37° C., at single or multiple wavelengths. It will be understood that optimum incubation time and temperature may vary for different plasma proteins.
Only 5 μL of sample and 60 μL of antibody reagent is required. It will be understood that optimum sample and reagent volumes may vary for different proteins.
In another aspect of the invention, the same dispensing tip used to aspirate 5 μL of sample is sealed at the lower end by increasing the vacuum on the tip by an equivalent of 4 μL. It will be understood that deviations from this volume are within the scope of this invention, particularly when other disposable tips are used. The extra vacuum equivalent to an aspiration of 4 μL, is sufficient to pull the fluid away from the lower end of the tip which is within the grasp of the jaws of a small vice without trapping air below the 5 μL of sample, and without trapping sample below or within the seal.
According to a preferred embodiment the jaws are slightly nonparallel as shown in
In practising the invention, an antibody reagent is mixed with the sample by injecting 60 μL of antibody reagent into 5 μL of a sample. Preferably, 60 μL of antibody reagent is in a narrow pipette tip, e.g., as shown as 4 in
Zero-time absorbance measurement is triggered after antibody reagent is dispensed into a sealed tip of the invention, and the zero-time measurement is performed with the dispensing stem attached to the tip.
According to one embodiment of the invention, the tip holder has a sliding lid which closes after antibody reagent is dispensed.
In another aspect of the invention, because of the location of the shutters in the lamp assembly the subtraction of dark current from both the sample and the reference light measurements, can effectively eliminate the effect of room light. Preferably the sample chamber is shielded from light but is not required to be completely light-tight; a cover may not be necessary in an automated system, where the dispenser stem, when inserted into the dispensing tip, can provide sufficient light shielding, even when dark current is not subtracted.
In another embodiment of the invention, the spectrometer can be run in single-beam mode.
In another aspect of an alternative embodiment of the invention, zero-time measurement is used as the reference scan when the spectrometer is run in the single-beam mode. Preferably the rate of change of the first derivative of absorbance is monitored during the first 15 seconds, to forecast if a high-dose hook effect will occur.
Immunoturbidimetric measurements are performed using multiple wavelengths in the visible and NIR electromagnetic radiation.
A method of the invention provides for measuring the concentration of a series of proteins in a sample by recording the absorbance spectrum of the sample before and after incubation with antibodies specific to each protein. Preferably the effect of interferents in a sample can be minimized by virtue of the wavelength range used, i.e., NIR and adjacent visible radiation. More preferably the remaining effect of interferents can be substantially removed by subtracting the first derivative of absorbance at zero time from the first derivative of absorbance after a two-minute incubation at 37° C. It will be understood that other tines and incubation temperatures can be used.
The effect of small air bubbles on absorbance is minimized by using the first derivative of absorbance. It will be understood that any higher order of derivative of absorbance may also be used, eg., second derivative of absorbance.
A system incorporating the apparatus of the present invention is generally illustrated in
Cover 100 in
For the measurement of proteins by immunoturbidimetry, a separate sample holder such as that illustrated (98) is required, and is imbedded in a heated block. In a preferred embodiment, 5 μL of plasma is aspirated in a dispensing tip, as shown as 1 in
In this invention, analytes are measured on the apparatus through the use of reagents by the process of immunoturbidimetry. Each protein requires a specific antibody, and the specificity of each test can be increased by subtracting the first derivative of the absorbance at zero time from the first derivative of absorbance after approximately 2 minutes at 37° C., at a single or multiple wavelengths. It will be understood that optimum incubation time and temperature could vary for different proteins.
60 μL of antibody reagent is aspirated from a bottle into a narrow pipette tip shown as 4 in
The disposable dispensing tip of an analyzer is used as a reaction and incubation chamber after the tip is sealed with the sample inside; it is also used as a cuvette. Although
Zero-time absorbance measurement is triggered after the antibody reagent is dispensed, with the dispensing stem attached to the tip. In another embodiment of the invention, the tip holder has a sliding lid which closes after the antibody reagent is dispensed, and after the dispensing stem releases the tip. The effect of interferents can be substantially removed by subtracting the first derivative of the absorbance at zero time from the first derivative of absorbance after a two-minute incubation at 37° C. It will be understood that other times and incubation temperatures can be used. I this design, the sample holder functions as both the incubator and the optical read station. It will be understood that the incubation can occur in a separate chamber, where the incubated sample can be aspirated into a disposable dispensing tip, which is subsequently placed in the tip holder 98 as shown in
Sample fibres 44 and 46 direct radiation from a light source to and from the sample respectively, and allow the bulk of the instrumentation to be placed remotely from the samples. Multiple optical fibres 46 and 48 are the strands of a bifurcated optical fibre which collect radiation alternately from the sample 44 and reference optical fibre 66, and combines into one multiple optical fibre 54 which communicates with a spectrometer 14. Reference fibre 66 is joined to a strand 48 of the bifurcated fibre by a coupling 52. The coupling 52 can be chosen to provide sufficient attenuation of the reference beam, where the detector is optimally integrated over a short period of time. Fibre 66 is a single fibre and fibre 44 can be a single or multiple fibres, depending on the light throughput required.
Referring to
Referring to
The sample and reference beams enter arms 46 and 48 respectively of a bifurcated optical multi-fibre bundle which combine in fibre 54 and are focused alternately onto a slit 70, by a focusing lens 68 and a shaping filter 69. Emerging radiation is collimated by lens 72 before the beam is directed to grating 74 which is a dispersing element which separates out component wavelengths in a preferred embodiment dichromated gelatin is used as the grating material. Component wavelengths are focused by a lens 76, onto the PDA 78. Each element or pixel of the PDA is set to receive and collect a predetermined wavelength. In a preferred embodiment the PDA comprises 256 pixels. The pixels are rectangular in shape to optimize the amount of optical radiation detected.
Spectrometer 14 is preferably a “dual-beam-in-time” spectrometer with fixed integration time for the reference beam and a choice of integration for the sample beam. Because the sample is only shielded from light, but is not in a light-tight holder, sample and reference dark scans can be subtracted from sample and reference light scans respectively; sample and reference dark scans are performed at the same integration times used for the respective light scans. In a preferred embodiment, the reference scan is performed at 13 milliseconds, and the sample scan is performed in 20 milliseconds; the maximum ADC value obtained at 20 milliseconds for a particular sample, is used to determine a new integration time up to 2600 milliseconds, such that saturation of the detector at any pixel does not occur. The maximum time allowed for any sample depends on the required speed of sample screening. Also, multiple scans can be averaged to minimize noise, but for interferent and protein measurements, the number of scans averaged must not require more than 1 second.
When in use, each pixel or wavelength portion is measured approximately simultaneously during a particular scan. Optical radiation falling on each sensor element is integrated for a specified time and individual pixels or wavelengths are samples sequentially by a 16 bit analog-to-digital convertor or ADC.
Although the present embodiment details use of a PDA, any alternative means which achieves the same result is within the scope of the present invention. For example a filter-wheel system may be used. In carrying out measurements each analyte uses from one to three wavelengths or pixels. Given that the first derivative of absorbance with respect to measurements with the PDA is the difference between the absorbance at two adjacent pixels, the first derivative of absorbance at one wavelength with a filter-wheel system will require absorbances measured with two different narrow band-pass filters. It will be readily understood by those skilled in the art that the filters do not need to be assembled on a rotating wheel, but that any structure which achieves the result of a narrow band-pass filtration of absorbed radiation is within the scope of the present invention.
The PDA integrates the optical radiation over a specified time and converts the optical signal to a time multiplexed analog electronic signal called scan where absorbance is calculated as:
Absorbance=log(Referencei/Sample measurementi)+log(ITM/ITR)
Depending upon the amount of light shielding provided by the apparatus and the criticality of timing, the measurement of a reference dark and sample dark values may or may not be undertaken. The electronic signal is proportional to the time that the sensor integrates the optical signal. The electronic signal is amplified by analog electronic amplifiers and converted to a digital signal by an analog-to-digital converter or ADC. The digital information from the converter is interpreted for data analysis by a microprocessor which is in him connected via an RS232 connector to a computer 84. The results of the data analysis can be shown on an output device such as a display and on a printer.
The first part of the process for generating a calibration curve is to store spectral data for the calibration set. The calibration algorithm for each protein must be installed in a microprocessor so that when an unknown sample is tested for a particular protein the result is quickly produced in order to calculate the quantity of any protein present, any one of several different methods, all of which are within the scope of this invention, may be used.
A preferred method is to calculate the first derivative of certain portions of the spectra in respect of the particular protein being measured. It is also possible to calculate the second, or third derivatives, and such calculations are within the scope of this invention. However, each step of taking differences to calculate those derivatives is more time consuming and introduces more noise.
In practice, an optimal combination of first derivatives of at least two portions of a spectrum generated from a scan for a particular protein are used to calculate protein concentration. The precise approach used depends on the protein being measured.
With respect to generating a calibration curve for IgA, 5 μL of each calibrator was aspirated in a Vitros dispensing tip using an Eppendorf pipette. The pipette setting was changed from 5 μL to 9 μL; this extra vacuum allowed the sample to be drawn away from the end of the tip which is within the grasp of the vice shown in
Similarly, calibration algorithms were developed β2-microglobulin and C-reactive protein, and their linear regression fits are shown in
Due to the small absorbances which is expected at the wavelengths used, the zero-time absorbance spectra obtained for IgA were observed to be in a random order, as shown in
In respect of IgA, optimal results may be obtained by calculating the first derivative of absorbance at wavelengths of approximately 789 nm and 825 nm. In respect of β2-microglobulin, optimal results may be obtained by calculating the first derivative of absorbance at wavelengths of approximately 548 nm and 829 nm. In respect of CRP, optimal results may be obtained by calculating the first derivative of absorbance at wavelengths of approximately 661 nm and 679 nm.
The calibration algorithm developed for IgA based on 4 calibrators is as follows;
mgIL IgA=−3327114.33(789 nm)+484270.80(825 nm)−77.3
where (X nm) is the first derivative of the absorbance at the wavelength specified.
The calibration algorithm developed for β2-microglobulin based on 7 calibrators is as follows:
mg/L β2-microglobulin=−33648.79(548 nm)+36556.81(829 nm)+2.3
where (X nm) is the first derivative of the absorbance at the wavelength specified.
The calibration algorithm developed for CRP based on 9 calibrators is as follows:
mgL CRP=−1813682.71(661 nm)+1808677.58(679 nm)+9.8
where (X nm) is the first derivative of the absorbance at the wavelength specified.
It will be understood that several calibration algorithms can be developed for each protein, using an apparatus described for measuring specimen integrity.
The protein measurements are based on the principle of immunoturbidimetry, i.e., generation of antibody-antigen complexes or immunocomplexes which cause turbidity. The “absorbance” generated is due to light scattering caused by the immunocomplexes, therefore endogenous turbidity or true absorbances caused by interferents in the sample will falsely elevate the signals. To demonstrate how interferents are dealt with, an aqueous solution of 2 g/L IgA was nixed with IL to provide 4 different samples with 1 g/L IgA and variable amounts of IL, i.e. from 0 to 4 g/L. Separate algorithms were developed for IgA with and without zero time correction.
The error in the predicted results with and without zero time subtraction is shown in
While the invention has been particularly shown and described with reference to preferred embodiments, it will be understood by those skilled in the art that various other changes in form, and detail may be made without departing from the scope of the invention.
Number | Date | Country | |
---|---|---|---|
60078780 | Mar 1998 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 09664704 | Sep 2000 | US |
Child | 10141377 | May 2002 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10141377 | May 2002 | US |
Child | 11691287 | Mar 2007 | US |
Parent | PCT/CA99/00236 | Mar 1999 | US |
Child | 09664704 | Sep 2000 | US |